FFA
MTNB icon

Farther Finance Advisors’s Matinas BioPharma MTNB Stock Holding History

Farther Finance Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Sell
5
-417
-99% -$261 ﹤0.01% 5727
2025
Q4 		$247 Hold
422
– – ﹤0.01% 5177
2025
Q3 		$798 Buy
422
+417
+8,340% +$599 ﹤0.01% 4436
2025
Q2 		$4 Hold
5
– – ﹤0.01% 4471
2025
Q1 		$3 Buy
+5
New +$3 ﹤0.01% 4242

Other funds holding MTNB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Farther Finance Advisors's MTNB Position: Q1 2026 in Review

Farther Finance Advisors reduced its Matinas BioPharma (MTNB) stake by 99% in Q1 2026, selling an estimated $261 and leaving 5 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5727.

Farther Finance Advisors first reported a position in MTNB in Q1 2025 and has held it in 5 quarters since. The position peaked at $798 in Q3 2025. 28 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.

  • Farther Finance Advisors held 5 shares of Matinas BioPharma worth $3 as of Q1 2026.
  • Farther Finance Advisors sold 417 Matinas BioPharma shares in Q1 2026, an estimated $261.
  • Matinas BioPharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q1 2026, its #5727 holding.
  • Farther Finance Advisors first reported a position in Matinas BioPharma in Q1 2025 and has held it in 5 quarters since.
  • Farther Finance Advisors's Matinas BioPharma position peaked at $798 in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.